Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (NCT04417621)

🧪 Interventions in This Study

• LXH254 (DRUG)
• LTT462 (DRUG)
• Trametinib (DRUG)
• Ribociclib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (36 Sites)

Showing the first 25 of 36 sites.

• The Angeles Clinic and Research Institute — Los Angeles, California
• UCSF Medical Center — San Francisco, California
• Florida Cancer Specialists — Fort Myers, Florida
• H Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
• Massachusetts General Hospital — Boston, Massachusetts
• Dana Farber Cancer Institute — Boston, Massachusetts
• Mayo Clinic Mayo Rochester — Rochester, Minnesota
• Mayo Clinic Rochester — Rochester, Minnesota
• NYU Laura and Isaac Perlmutter Cancer Center — New York, New York
• Memorial Sloan Kettering — New York, New York
• University of Pittsburgh Med Center — Pittsburgh, Pennsylvania
• Univ of TX MD Anderson Cancer Cntr — Houston, Texas
• Novartis Investigative Site — CABA, Buenos Aires
• Novartis Investigative Site — North Sydney, New South Wales
• Novartis Investigative Site — Wooloongabba, Queensland
• Novartis Investigative Site — Subiaco, Western Australia
• Novartis Investigative Site — Leuven,
• Novartis Investigative Site — Wilrijk,
• Novartis Investigative Site — Lille,
• Novartis Investigative Site — Marseille,
• Novartis Investigative Site — Paris,
• Novartis Investigative Site — Pierre-Bénite,
• Novartis Investigative Site — Toulouse,
• Novartis Investigative Site — Villejuif,
• Novartis Investigative Site — Dresden, Saxony

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Melanoma

• Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy — San Francisco, California
• An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) — Tucson, Arizona
• Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. — CABA, Buenos Aires
• Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients — Santa Monica, California
• NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma — Boston, Massachusetts
• A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Orlando, Florida

Explore by condition: All Melanoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.